Clinical trials: Chemotherapy-Related Nausea and/or Vomiting
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer.
- Trial name
- NCT05838638
- Testing
- eSSET-CINV
- Where
- 2 sites in United States
- Volunteers
- 610 people
- Sponsor
- University of Central Florida
Cancer, Malignancy
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
The purpose of this study is to assess the efficacy and safety of Ramosetron, Aprepitant and Dexamethasone therapy versus Ondansetron, Aprepitant and Dexamethasone therapy for preventing of nausea and vomiting in highly…
- Trial name
- ROAD (NCT01536691)
- Testing
- ramosetron, ondansetron
- Where
- South Korea
- Volunteers
- 338 people
- Sponsor
- Hallym University Medical Center
Chemotherapy-induced Nausea and Vomiting
Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail
This is a randomized, controlled cross-over trial. The hypothesis of this study is that the differences in manual acupuncture manipulation can impact clinical effect though the acupuncturists follow the same needling regimen.
- Trial name
- ACTIN (NCT02127255)
- Testing
- Manual acupuncture implemented by acupuncturist 1, Manual acupuncture implemented by acupuncturist 2
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Beijing University of Chinese Medicine
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an…
- Trial name
- NCT02557035
- Testing
- Palonosetron, Dexamethasone
- Where
- 76 sites in Belarus, Bosnia and Herzegovina and 7 more
- Volunteers
- 441 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Nausea and Vomiting Chemotherapy-Induced, Hematological Malignancies
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting
The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting in Patients With Hematological Malignancies ABSTRACT Background: Chemotherapy is widely used in the treatment of hematological malignancies…
- Trial name
- NCT07456982
- Testing
- Relaxation breathing exercise, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people
- Sponsor
- Marmara University
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients receiving chemotherapy for cancer. PURPOSE: This randomized phase II trial is studying how well ginger works in reducing or preventing…
- Trial name
- IRB 2003-551 (NCT00064272)
- Testing
- ginger extract
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 180 people
- Sponsor
- University of Michigan Rogel Cancer Center
Emesis
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
For breast cancer patients receiving chemotherapy regimens, the use of a validated emesis (nausea and vomiting) risk calculator will provide superior anti-emetic (nausea and vomiting) control compared with "standard" anti-emetic…
- Trial name
- ER11-02 (NCT01913990)
- Testing
- Dexamethasone, Ondansetron, Aprepitant, Arm A: Standard Anti-emetic regimen
- Where
- Canada
- Volunteers
- 323 people
- Sponsor
- Ottawa Hospital Research Institute
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
The objective of this study is to compare the effectiveness of olanzapine added to standard triplet therapy (fosaprepitant, ondansetron, and dexamethasone) versus triplet therapy alone in preventing chemotherapy-induced nausea…
- Trial name
- FOND-O (NCT02635984)
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Augusta University
Chemotherapy Induced Nausea and Vomiting
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children…
- Trial name
- NCT02097823
- Testing
- Olanzapine, Aprepitant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Nausea, Vomiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07169851
- Testing
- LY3537021, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Chemotherapy-induced Nausea and Vomiting
Prevalence of Delayed Chemotherapy Associated Nausea
This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.
- Trial name
- CINrate (NCT04342780)
- Where
- Switzerland
- Volunteers
- 172 people
- Sponsor
- Antje Koller
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.
- Trial name
- NCT01596400
- Testing
- granisetron transdermal system, Granisetron IV
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Pediatric Cancer
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
The purpose is to evaluate the effectiveness and safety of fosaprepitant plus ondansetron with dexamethasone or placebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE…
- Trial name
- NCT04508400
- Testing
- Fosaprepitant,ondansetron, dexamethasone
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-induced Nausea and Vomiting
Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting
This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.
- Trial name
- NCT05143554
- Testing
- Auricular percutaneous neurostimulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
to Evaluate the Effectiveness of Acupucnture in the Management of Chemotherapy-induced Nausea and Vomiting
The Different Effectiveness of Single Acupoint（PC6 or CV12) vs Matching Acupoints(PC6 and CV12) in Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to clarify whether the matching acupoints are more effective than a single point by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting .
- Trial name
- NCT02195908
- Testing
- single point Neiguan(PC6) plus antiemetic drug, single point Zhongwan(CV12) plus antiemetic drug, matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tianjin University of Traditional Chinese Medicine
Lymphoma, Non-Hodgkin
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented.
- Trial name
- NCT01843868
- Testing
- Standard anti-emetics in conjunction with R-CHOP
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Chemotherapy-induced Nausea and Vomiting
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple…
- Trial name
- NCT02434861
- Testing
- Rolapitant, Digoxin, Sulfasalazine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.